Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
January 21st, 2020
Provided here is a protocol that details steps to establish an animal model of chronic post-ischemia pain (CPIP). This is a well-recognized model mimicking human complex regional pain syndrome type-I. Mechanical and thermal hypersensitivities are further evaluated, as well as capsaicin-induced nocifensive behaviors observed in the CPIP rat model.
The mechanism underlying CRPS I still remain unclear. Establishing a preclinical animal model mimicking CRPS I will be crucial for exploring the mechanisms underlying CRPS I.The rat CPIP model exhibits many CRPS I like simitance, which include hindlimb edema and hyperemia in the early stage. After model establishment, followed by persistent thermal and mechanical hypersensitivities.
Begin by anesthetizing all rats with sodium phenobarbital. Make sure that the rats are properly anesthetized by pinching their hind paw or tail with forceps. And place vet ointment on the eyes.
Keep the rat on a 37 degree Celsius heated pad during the procedure. Lubricate the right hind paw and ankle with glycerol. Then slide a nitrile 70 durometer O ring into the larger side of a one point five milliliter tube with the snap cap cut off.
Carefully insert the hind paw into the hollow tube until it reaches the bottom. Gradually slide the O ring from the tube to the right hindlimb near the ankle joint. And leave it there for three hours.
Apply the same treatment to the sham group of rats, except with a broken O ring that should not induce ischemia. After three hours, cut off the O ring and monitor the rat until it regains enough consciousness to maintain sternal recumbency. Do not place the rat in the company of other rats until it is fully recovered from anesthesia.
Place the rat in a transparent plexiglass chamber on a mesh floor, and habituate the rat to the environment for 30 minutes before any behavioral testing. Use von frey filaments to test the rat for mechanical allodynia. Begin the test from the middle filament by vertically applying it to the middle plantar surface of the hind paw.
Apply suitable force to bend the filament for up to five seconds. A sudden retraction of the paw is considered a nocifensive behavior. Conduct the mechanical allodynia test on days three, two, one, and every other day until day 13.
Apply the up down testing method to test the threshold and a dickson method for calculating the 50 percent paw withdrawal threshold. To test for thermal hyperalgesia, use hargreaves method by directly aiming the light beam emitted from a 50 watt bulb to the hind paw. Measure the paw withdrawal latency, setting 20 seconds as the cutoff threshold to avoid excessive injury.
Repeat each test three times in five minute intervals for each hind paw, and take the average as the paw withdrawal latency. Conduct the thermal hyperalgesia test on days three, two, one, and every other day until day 13. To test for capsaicin induced acute nocifensive behavior, prepare the 200 millimolar capsaicin stock solution with DMSO, and further dilute it one to 1, 000 in PBS for injection.
Capsaicin is a reagent, which can cause joint irritation to skin, eyes, and respiration. It's important to wear a mask and goggle when preparing capsaicin solution. Then inject 50 microliters of the capsaicin or a vehicle into the hind paw using a 30 gauge needle attached to a one milliliter syringe.
Record nocifensive behavior, such as licking, biting, or flinching of the injected paw using a video camera for 10 minutes after the injection. Evaluate hind paw edema by measuring the increase in paw diameter at 15 minutes, 24 hours, 48 hours, and 72 hours after model establishment. After placing the O ring on the ankle, the ipsilateral hind paw skin showed cyanosis, an indication of tissue hypoxia.
After cutting the O ring, the paw began to fill with blood and showed robust swelling, indicating intense hyperemia. The swelling gradually diminished and returned to normal 48 hours after the procedure. One day after model establishment, the ipsilateral hind paw of the CPIP group exhibited obvious mechanical allodynia that persisted for 13 days of the observation time frame.
The contralateral hind paw of the CPIP group also displayed mechanical hyperalgesia for 13 days. When thermal hyperalgesia was measured, bilateral hind paws of CPIP rats exhibited significantly reduced withdrawal latency in response to noxious thermal stimuli, compared to the sham group rats. The thermal hyperalgesia of the ipsilateral hind paw persisted until the end of the observation time frame, whereas the thermal hyperalgesia of the contralateral hind paw lasted for seven days.
The sham and CPIP groups were tested for nocifensive behavior with the capsaicin injection. When a vehicle was injected, the sham group showed a slight nocifensive response and the CPIP group showed a significantly higher response. More importantly, CPIP rats showed significantly higher responses to capsaicin injection than the sham group, which suggests that the CPIP rats exhibit a phenomenon similar to human patients with CRPS I.By this procedure, the rats are anesthetized before and during model establishment.
The CPIP rat model described in this protocol established by ischemia and Human CRPS I like simitance. Families of these models, more mechanism about CRPS I can be explored.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol outlines the establishment of a chronic post-ischemia pain (CPIP) animal model, which closely resembles human complex regional pain syndrome type-I. The model allows for the evaluation of mechanical and thermal hypersensitivities, as well as the observation of capsaicin-induced nocifensive behaviors.
Key Study Components
Area of Science
- Neuroscience
- Pain Research
- Animal Models
Background
- Chronic post-ischemia pain (CPIP) is a model for studying complex regional pain syndrome type-I (CRPS I).
- The mechanisms underlying CRPS I remain unclear.
- Establishing a preclinical animal model is crucial for exploring these mechanisms.
- The CPIP rat model exhibits symptoms similar to CRPS I, including hindlimb edema and hyperemia.
Purpose of Study
- To establish a reliable animal model for chronic post-ischemia pain.
- To evaluate hypersensitivity responses in the CPIP model.
- To facilitate further research into the mechanisms of CRPS I.
Methods Used
- Anesthetizing rats with sodium phenobarbital.
- Confirming proper anesthesia through physical response tests.
- Applying veterinary ointment to protect the eyes during the procedure.
- Monitoring for persistent thermal and mechanical hypersensitivities post-model establishment.
Main Results
- The CPIP model successfully mimics key symptoms of CRPS I.
- Rats exhibit significant mechanical and thermal hypersensitivities.
- Capsaicin-induced nocifensive behaviors are observable in the model.
- Hindlimb edema and hyperemia are present in the early stages.
Conclusions
- The CPIP rat model is a valuable tool for studying CRPS I.
- It provides insights into the mechanisms of chronic pain syndromes.
- This model can aid in the development of potential therapeutic strategies.
Frequently Asked Questions
Executive Industry Relevance
The rat chronic post-ischemia pain (CPIP) model provides a preclinical system to investigate complex regional pain syndrome type-I (CRPS-I) mechanisms, addressing a critical gap in neuropathic pain drug discovery. By replicating ischemia-reperfusion-induced hypersensitivity and capsaicin sensitization, the model supports target validation and mechanistic de-risking in early analgesic development. Its phenotypic alignment with human CRPS-I enables predictive confidence for portfolio prioritization in pain therapeutics.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses related to ischemia-reperfusion pathways in neuropathic pain.
- Operational Value: Supports biological de-risking through phenotypic validation of mechanical and thermal hypersensitivity.
- Scientific Value: Facilitates functional target validation via capsaicin-induced nocifensive response quantification.
Screening & Assay Development
- Scientific Value: Establishes standardized, reproducible behavioral readouts for mechanical allodynia and thermal hyperalgesia.
- Operational Value: Provides quantitative dependent variables (paw withdrawal latency, nocifensive behavior duration) for assay optimization.
- Scientific Value: Enables screening readiness through longitudinal hypersensitivity tracking up to 13 days post-modeling.
Translational & Preclinical Research
- Scientific Value: Models disease-relevant manifestations including edema, hyperemia, and persistent sensitization mirroring CRPS-I.
- Operational Value: Supports translational biomarker alignment via capsaicin response as a proxy for sensory hypersensitivity.
- Scientific Value: Enables risk-adjusted advancement decisions by quantifying hypersensitivity persistence and bilateral spread.
Pipeline & Workflow Integration
The CPIP model fits within the discovery continuum from target hypothesis testing through lead identification to preclinical efficacy evaluation in neuropathic pain programs.
- Discovery Biology: Supports mechanistic interrogation of ischemia-reperfusion injury pathways driving persistent pain.
- Screening: Delivers assay-ready, standardized hypersensitivity phenotypes for compound effect evaluation.
- Analytics: Generates longitudinal, quantitative hypersensitivity metrics enabling intergroup comparison and effect size calculation.
- Translational Research: Connects to preclinical validation through phenotypic continuity with human CRPS-I sensory and autonomic symptoms.
- Enterprise Reuse: Functions as a reusable platform for iterative target validation across analgesic modality classes.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by modeling ischemia-reperfusion as a mechanistic driver of CRPS-I-like pain.
- Operational Value: Ensures reproducibility through standardized ischemia duration, behavioral testing cadence, and blinded assessment.
- Strategic Value: Improves go/no-go decisions by quantifying target engagement via hypersensitivity reversal.
- Portfolio Impact: Enables risk-adjusted prioritization based on model sensitivity to known analgesic mechanisms.
Implementation Considerations
- Requires expertise in rodent surgery, ischemia-reperfusion techniques, and behavioral pain assessment.
- Depends on calibrated von Frey filaments, Hargreaves apparatus, and video tracking for nocifensive behavior quantification.
- Necessitates standardized habituation, testing timing, and environmental controls to minimize variability.
- Involves adaptation considerations when translating rat hypersensitivity metrics to other species or pain models.
- Limited by model specificity to ischemia-reperfusion etiology, which may not capture all CRPS-I pathophysiological subtypes.
![Autoradiographic Measurements of [14C]-Iodoantipyrine in Rat Brain Following Central Post-Stroke Pain](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F53947.jpg%3Fv%3D2026-07-03T15%253A55%253A54.000Z&w=384&q=75)
